Telomir Pharmaceuticals, Inc | WebDisclosure

Basculer en Français

10813	Companies
234250	Keywords
163043	Articles
125263	Press releases

Headlines Articles Press releases Telomir Pharmaceuticals, Inc

Home
Companies
Telomir Pharmaceuticals, Inc

PRESS RELEASE

published on 10/09/2025 at 13:30, 10 months ago

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
Telomir Pharmaceuticals announces new findings showing Telomir-1's impact on aggressive breast cancer cells, targeting iron-dependent regulation and cellular energy pathways

Telomir-1 Telomir Pharmaceuticals Breast Cancer Cells Iron-dependent Regulation Cellular Energy Pathways
BRIEF

published on 10/07/2025 at 13:35, 10 months 2 days ago

Telomir Pharmaceuticals dévoile des résultats précliniques prometteurs dans le traitement du cancer de la prostate

Cancer De La Prostate Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Suppresseurs De Tumeurs
BRIEF

published on 10/07/2025 at 13:35, 10 months 2 days ago

Telomir Pharmaceuticals Unveils Promising Preclinical Results in Prostate Cancer Therapy

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Tumor Suppressors
PRESS RELEASE

published on 10/07/2025 at 13:30, 10 months 2 days ago

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Telomir Pharmaceuticals unveils new preclinical findings showing Telomir-1 reactivates tumor suppressor genes MASPIN and RASSF1A in aggressive prostate cancer models, offering potential for improved chemotherapy response and metastasis control

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Preclinical Findings Tumor Suppressor Genes
BRIEF

published on 09/18/2025 at 14:05, 10 months 21 days ago

Telomir-1 Shows Expanded Targeting of Histone Demethylases

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Histone Demethylases Cancer And Aging
BRIEF

published on 09/18/2025 at 14:05, 10 months 21 days ago

Telomir-1 montre un ciblage élargi des déméthylases d'histones

Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Histone Demethylases Cancer Et Vieillissement
PRESS RELEASE

published on 09/18/2025 at 14:00, 10 months 21 days ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
Telomir Pharmaceuticals announces Telomir-1's new in vitro results inhibiting KDM5 family, expanding epigenetic therapy possibilities in cancer treatment and aging slowdown

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy KDM5 Family Inhibition Cancer Aging Treatment
BRIEF

published on 09/09/2025 at 14:05, 11 months ago

Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data

Cancer Research Telomir-1 Telomir Pharmaceuticals DNA Methylation CDKN2A
BRIEF

published on 09/09/2025 at 14:05, 11 months ago

Telomir Pharmaceuticals dévoile des données précliniques prometteuses sur le cancer

Telomir-1 Telomir Pharmaceuticals Recherche Sur Le Cancer Méthylation De L'ADN CDKN2A
PRESS RELEASE

published on 09/09/2025 at 14:00, 11 months ago

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
Telomir Pharmaceuticals announces new preclinical findings showing Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, potentially restoring cancer cell cycle control and immune surveillance

Cancer Therapy Telomir Pharmaceuticals Preclinical Findings DNA Methylation CDKN2A Gene

Accesswire

Published on 08/08/2026 at 00:00, 1 day 18 hours ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 1 day 19 hours ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 1 day 19 hours ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 1 day 20 hours ago

UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 1 day 20 hours ago

Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services

View all ACCESSWIRE

EQS Group

Published on 08/09/2026 at 15:05, 3 hours 44 minutes ago

GearUP and Escape from Tarkov Partner to Enhance Online Gaming Experience for the New Season
Published on 08/09/2026 at 00:01, 18 hours 48 minutes ago

Club Offers for Travel Enthusiasts in Germany
Published on 08/08/2026 at 16:25, 1 day 2 hours ago

Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 1 day 19 hours ago

EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 1 day 23 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 08/07/2026 at 18:54, 1 day 23 hours ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 1 day 23 hours ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 2 days ago

Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 2 days ago

Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 2 days ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026

View all LES ECHOS COMFI WIRE